Plus Therapeutics Inc (PSTV) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Plus Therapeutics Inc   (NASDAQ: PSTV)


Plus Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Plus Therapeutics Inc's ROI in the second quarter of 2026?
Plus Therapeutics Inc recorded a cumulative net loss of $-26 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -378.02%.

Within the Healthcare sector 212 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 4528 to 4869.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 5 13 4 5 3
Return On Investment (TTM) -378.02 % -189.56 % -659.33 % -12940.88 % 793.45 %
PSTV's Overall Ranking # 4869 # 4528 # 3890 # 3872 # 0
Seq. Investment Change TTM 9.65 % 85.38 % 2035.38 % - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -26 -12 -22 -21 -19

PSTV Company Profile >> Back to PSTV Roi Comparisons >> See Annual PSTV Return On Investment



Return On Investment PSTV's Ranking
Within: No.
Industry # 62
Sector # 213
Overall # 4869

Return On Investment Statistics
High Average Low
-6.92 %
-556.82 %
-12339.43 %
(Mar 31 2016)   (Sep 30 2025)



  News about Plus Therapeutics Inc Return on Investment ROI

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons ...

October 1, 2024

News Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting In a pivotal presentation at the 2024 Congress of Neurological Surgeons Annual Meeting, Plus Therapeutics, Inc. disclosed significant updates regarding its ongoing ReSPECT-GBM clinical trial, aimed at assessing the efficacy of its investigational therapy for glioblastoma multiforme (GBM). The trial seeks to investigate innovative approaches in the fight against one of the most challenging forms of brain cancer.Despite the promising advancements in its clinical programme, Plus Therapeutics has faced substantial financial hurdles. The company reported a cumulative net loss of $15 million for the twelve months ending in September 2023. This unfortunate development has culminated in an alarming return on investment (ROI) of -303.66%, positioning Plus Therapeutics unfavourably against its peers in the healthcare sector. Indeed, 918 other companies have recorded a more favourable ROI, further underscoring the financial challenges faced by Plus Therapeutics.

Plus Therapeutics Inc Bolsters Management Team with Leading Neuro-Oncologist and Distinguished Ph.D., Aims for Innovation and Growth

April 9, 2024

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus Management Team
The healthcare industry is constantly evolving and advancing, and it is essential for companies to have access to experts in key areas. Plus Therapeutics Inc, a leading pharmaceutical company, has recently announced the addition of two highly accomplished professionals to their internal team. Dr. Andrew Brenner, a renowned Neuro-Oncologist, and Dr. Barbara Blouw, a distinguished Ph.D., are joining Plus to expand the company s expertise and drive innovation.
The inclusion of Dr. Brenner and Dr. Blouw in the Plus management team is expected to have a significant impact on the company’s growth and success. Dr. Brenner brings a wealth of experience and knowledge in neuro-oncology, a specialized field that focuses on brain and spinal cord tumors. His expertise will be invaluable in developing groundbreaking treatments and therapies for patients with these complex conditions.





Financial Statements
Plus Therapeutics Inc's II. Quarter Investments $ 5 Millions PSTV's Balance sheet
Plus Therapeutics Inc's II. Quarter Income $ -9 Millions Quarterly PSTV's Income Statement
PSTV's Income by Division See PSTV's Income by Division


PSTV Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 4 -9 1 12 16
Y / Y Investment Growth - - -94.5 % -25.42 % 351.79 %
Net Income in Millions -22 -13 -13 -20 -13
Y / Y Net Income Growth - - - - -
Annual Return On Investment -560.21 % - -2014.52 % -168.75 % -83.17 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PSTV's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PSTV's Competitors
Subscribers only: Roi for Plus Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for PSTV's Customers

Other Ratios
PSTV's Roa PSTV's Inventory Turnover Ratio PSTV's Growth Rates PSTV's Dividend Statistics
PSTV's Profitability Ratios PSTV's Asset Turnover Ratio PSTV's Dividend Growth
PSTV's Roe PSTV's Valuation Ratios PSTV's Financial Strength Ratios PSTV's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:21:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.